RAPT — Rapt Therapeutics Share Price
0.000.00%
Last trade - 00:00- $319.81m
- $160.95m
- 29
- 19
- 17
- 11
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.18 | ||
| Price to Tang. Book | 2.18 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -83.87% | ||
| Return on Equity | -59.56% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 5.04 | 3.81 | 1.53 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.
Directors
- Brian Wong PRE (49)
- Rodney Young CFO (58)
- Dirk Brockstedt CSO (52)
- William Ho OTH (55)
- Michael Giordano IND (63)
- Mary Gray IND (68)
- Linda Kozick IND (63)
- Lori Lyons-Williams IND
- William Rieflin IND (61)
- Wendye Robbins IND (60)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 4th, 2015
- Public Since
- October 31st, 2019
- No. of Shareholders
- 33
- No. of Employees
- 131
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 34,799,702
- Address
- 561 Eccles Ave, SOUTH SAN FRANCISCO, 94080-1906
- Web
- https://rapt.com/
- Phone
- +1 6504899000
- Auditors
- Ernst & Young LLP
Upcoming Events for RAPT
RAPT Therapeutics Inc Annual Shareholders Meeting
Rapt Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Rapt Therapeutics Inc Earnings Release
Similar to RAPT
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Rapt Therapeutics share price?
As of Today at 19:18 UTC, shares in Rapt Therapeutics are trading at $9.19. This share price information is delayed by 15 minutes.
How has the Rapt Therapeutics share price performed this year?
Shares in Rapt Therapeutics last closed at $9.19 and the price had moved by -46.88% over the past 365 days. In terms of relative price strength the Rapt Therapeutics share price has underperformed the S&P500 Index by -57.1% over the past year.
What are the analyst and broker recommendations for Rapt Therapeutics?
The overall consensus recommendation for Rapt Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Rapt Therapeutics dividend yield?
Rapt Therapeutics does not currently pay a dividend.
Does Rapt Therapeutics pay a dividend?
Rapt Therapeutics does not currently pay a dividend.
When does Rapt Therapeutics next pay dividends?
Rapt Therapeutics does not currently pay a dividend.
How do I buy Rapt Therapeutics shares?
To buy shares in Rapt Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Rapt Therapeutics?
As of the previous close price of $9.19, shares in Rapt Therapeutics had a market capitalisation of $319.81m.
Where are Rapt Therapeutics shares listed?
Here are the trading details for Rapt Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: RAPT
What kind of share is Rapt Therapeutics?
Based on an overall assessment of its quality, value and momentum Rapt Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Rapt Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Rapt Therapeutics is $23.13. That is 151.69% above the last closing price of $9.19.
Analysts covering Rapt Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.22 for the next financial year.
What is the trend in the Rapt Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rapt Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -35.91%.
As of the last closing price of $9.19, shares in Rapt Therapeutics were trading -46.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Rapt Therapeutics PE Ratio?
The Rapt Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Rapt Therapeutics?
Rapt Therapeutics' management team is headed by:
- Brian Wong - PRE
- Rodney Young - CFO
- Dirk Brockstedt - CSO
- William Ho - OTH
- Michael Giordano - IND
- Mary Gray - IND
- Linda Kozick - IND
- Lori Lyons-Williams - IND
- William Rieflin - IND
- Wendye Robbins - IND